BioNTech broadens investor base with $325M B round

As it builds its pipeline beyond mRNA therapies, BioNTech broadens its investor base to Asia

While BioNTech remains quiet about a timeline for a potential listing, the German biotech has further broadened its investor base with multiple Asia-Pacific firms backing a $325 million series B round as it invests in pipeline programs and specialized manufacturing. The company’s seven clinical programs are all mRNA-based therapeutics, and it aims to start clinical studies of CAR T and small molecule programs within a year.

Long supported by the Strüngmann family office from its

Read the full 747 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE